Vitiligo is a skin disorder that results in the formation of depigmented patches or hypopigmented macules due to selective destruction or reduction of melanocytes the cells that produce pigment in our skin. Vitiligo affects 0.1-2% of the World's population. People of all skin types and all ages can be affecte. In most of the cases, white patches develop or expand slowly overtime, and in some cases it never progress and remains stable . Vitiligo can be segmental or non-segmental depending upon the morphology of the clinical involvement. It can also be classified as stable or unstable based on the activity of disease. Steroids act as anti-inflammatory and immunosuppressant agents. Even if different classes of steroids are now available, the mid- potent ones (e.g. betamethasone dipropionate 0.05% cream, 0.05% clobetasol propionate ointment) are usually preferred for the treatment of young patients . Now days, topical corticosteroids are the most commonly prescribed agents in treatment of dermatologic conditions .Almost all treatments of vitiligo have borrowed from therapies whose prime targets have been another disease.

What is being studied: drug — Beclomethasone.

Who can take part: ages 25 Years to 40 Years, 60 participants planned.

Enrollment status: the registry has not updated this study since its planned completion date, so its current status is unclear. The study started 10 November 2025 and was due to finish 10 February 2026.

Contact: Ola Sabry Abd-Elmaksoud Tarabya, MSc.

Source: ClinicalTrials.gov, NCT07267273 (https://clinicaltrials.gov/study/NCT07267273).